Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.39 USD
−526.24 M USD
7.53 M USD
113.56 M
About Cytokinetics, Incorporated
Sector
CEO
Robert I. Blum
Headquarters
South San Francisco
Website
Founded
1997
FIGI
BBG000F0R4N9
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
CYTK5615147
Cytokinetics, Incorporated 3.5% 01-JUL-2027Yield to maturity
−4.13%
Maturity date
Jul 1, 2027
CYTK4910847
Cytokinetics, Incorporated 4.0% 15-NOV-2026Yield to maturity
−22.31%
Maturity date
Nov 15, 2026
Explore more bonds
Frequently Asked Questions
The current price of CYTK is 47.78 USD — it has increased by 0.76% in the past 24 hours. Watch Cytokinetics, Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cytokinetics, Incorporated stocks are traded under the ticker CYTK.
CYTK stock has fallen by −4.22% compared to the previous week, the month change is a −11.10% fall, over the last year Cytokinetics, Incorporated has showed a 31.48% increase.
We've gathered analysts' opinions on Cytokinetics, Incorporated future price: according to them, CYTK price has a max estimate of 120.00 USD and a min estimate of 60.00 USD. Watch CYTK chart and read a more detailed Cytokinetics, Incorporated stock forecast: see what analysts think of Cytokinetics, Incorporated and suggest that you do with its stocks.
CYTK reached its all-time high on Jan 8, 2024 with the price of 110.25 USD, and its all-time low was 3.05 USD and was reached on Oct 13, 2014. View more price dynamics on CYTK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYTK stock is 3.50% volatile and has beta coefficient of 0.80. Track Cytokinetics, Incorporated stock price on the chart and check out the list of the most volatile stocks — is Cytokinetics, Incorporated there?
Today Cytokinetics, Incorporated has the market capitalization of 5.79 B, it has increased by 0.60% over the last week.
Yes, you can track Cytokinetics, Incorporated financials in yearly and quarterly reports right on TradingView.
Cytokinetics, Incorporated is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
CYTK earnings for the last quarter are −1.36 USD per share, whereas the estimation was −1.23 USD resulting in a −10.16% surprise. The estimated earnings for the next quarter are −1.24 USD per share. See more details about Cytokinetics, Incorporated earnings.
Cytokinetics, Incorporated revenue for the last quarter amounts to 463.00 K USD, despite the estimated figure of 1.21 M USD. In the next quarter, revenue is expected to reach 10.22 M USD.
CYTK net income for the last quarter is −160.54 M USD, while the quarter before that showed −143.32 M USD of net income which accounts for −12.02% change. Track more Cytokinetics, Incorporated financial stats to get the full picture.
No, CYTK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 423.00 employees. See our rating of the largest employees — is Cytokinetics, Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytokinetics, Incorporated EBITDA is −511.14 M USD, and current EBITDA margin is −6.43 K%. See more stats in Cytokinetics, Incorporated financial statements.
Like other stocks, CYTK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytokinetics, Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytokinetics, Incorporated technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytokinetics, Incorporated stock shows the neutral signal. See more of Cytokinetics, Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.